NZ545498A - Rapid dissolution formulation of a calcium receptor-active compound - Google Patents

Rapid dissolution formulation of a calcium receptor-active compound

Info

Publication number
NZ545498A
NZ545498A NZ545498A NZ54549804A NZ545498A NZ 545498 A NZ545498 A NZ 545498A NZ 545498 A NZ545498 A NZ 545498A NZ 54549804 A NZ54549804 A NZ 54549804A NZ 545498 A NZ545498 A NZ 545498A
Authority
NZ
New Zealand
Prior art keywords
weight
composition according
composition
hyperparathyroidism
chosen
Prior art date
Application number
NZ545498A
Other languages
English (en)
Inventor
Francisco J Alvarez
Glen Gary Lawrence
Hung-Ren H Lin
Tzuchi R Ju
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34434844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ545498(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NZ545498A publication Critical patent/NZ545498A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ545498A 2003-09-12 2004-09-10 Rapid dissolution formulation of a calcium receptor-active compound NZ545498A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50221903P 2003-09-12 2003-09-12
PCT/US2004/026732 WO2005034928A1 (en) 2003-09-12 2004-09-10 Rapid dissolution formulation of a calcium receptor-active compound

Publications (1)

Publication Number Publication Date
NZ545498A true NZ545498A (en) 2010-04-30

Family

ID=34434844

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ545498A NZ545498A (en) 2003-09-12 2004-09-10 Rapid dissolution formulation of a calcium receptor-active compound

Country Status (30)

Country Link
US (7) US7829595B2 (cg-RX-API-DMAC7.html)
EP (8) EP3395340B8 (cg-RX-API-DMAC7.html)
JP (3) JP5026077B2 (cg-RX-API-DMAC7.html)
KR (1) KR101332058B1 (cg-RX-API-DMAC7.html)
CN (1) CN1946382B (cg-RX-API-DMAC7.html)
AR (1) AR045637A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004279318C1 (cg-RX-API-DMAC7.html)
BR (2) BR122018013029B1 (cg-RX-API-DMAC7.html)
CA (1) CA2536487C (cg-RX-API-DMAC7.html)
CY (5) CY1119609T1 (cg-RX-API-DMAC7.html)
DE (1) DE19164145T1 (cg-RX-API-DMAC7.html)
DK (6) DK3395340T3 (cg-RX-API-DMAC7.html)
EA (1) EA013425B1 (cg-RX-API-DMAC7.html)
ES (7) ES2735226T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20130114T4 (cg-RX-API-DMAC7.html)
HU (5) HUE043958T2 (cg-RX-API-DMAC7.html)
IL (1) IL173737A (cg-RX-API-DMAC7.html)
IS (1) IS3027B (cg-RX-API-DMAC7.html)
MX (1) MXPA06002616A (cg-RX-API-DMAC7.html)
MY (1) MY142046A (cg-RX-API-DMAC7.html)
NO (1) NO335739B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ545498A (cg-RX-API-DMAC7.html)
PL (6) PL3260117T3 (cg-RX-API-DMAC7.html)
PT (6) PT3395339T (cg-RX-API-DMAC7.html)
SG (1) SG146608A1 (cg-RX-API-DMAC7.html)
SI (6) SI3395338T1 (cg-RX-API-DMAC7.html)
TR (4) TR201910180T4 (cg-RX-API-DMAC7.html)
TW (1) TWI344363B (cg-RX-API-DMAC7.html)
WO (1) WO2005034928A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200602710B (cg-RX-API-DMAC7.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045637A1 (es) 2003-09-12 2005-11-02 Amgen Inc Formulacion de disolucion rapida de un compuesto activo frente a los receptores de calcio
CA2881078C (en) 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2006125026A2 (en) * 2005-05-16 2006-11-23 Teva Pharmaceutical Industries, Ltd. Process for preparing cinacalcet hydrochloride
JP2008507567A (ja) * 2005-05-23 2008-03-13 テバ ファーマシューティカル インダストリーズ リミティド 非晶性シナカルセト塩酸塩及びその調製
EP1883618B1 (en) * 2005-05-23 2009-10-14 Teva Pharmaceutical Industries Ltd. Processes for preparing cinacalcet hydrochloride crystal form i
SI1884242T1 (sl) 2005-05-26 2013-07-31 Dainippon Sumitomo Pharma Co., Ltd. Farmacevtski sestavek, ki vsebuje lurazidon
CA2620469C (en) * 2005-09-02 2014-04-01 Amgen Inc. Methods of modulating intestinal fluid balance
EP1828098A1 (en) * 2005-11-22 2007-09-05 Teva Pharmaceutical Industries Ltd Crystal forms of cinacalcet hci and processes for their preparation
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
PT3095447T (pt) 2006-02-03 2022-01-24 Opko Renal Llc Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
MX2008012061A (es) * 2006-03-23 2008-12-17 Amgen Inc Metodos y composiciones para elaborar y utilizar polimorfos de cinacalcet.
TW200808297A (en) * 2006-04-27 2008-02-16 Teva Pharma Process for the preparation of cinacalcet base
EP1928817A1 (en) * 2006-04-27 2008-06-11 Teva Pharmaceutical Industries Ltd Process for the preparation of cinacalcet base
DK2037936T3 (da) 2006-06-21 2014-09-22 Opko Renal Llc Fremgangsmåde til behandling og forebyggelse af sekundær hyperparathyroidisme
WO2008000422A1 (en) * 2006-06-27 2008-01-03 Sandoz Ag Amorphous form of cinacalcet
WO2008027522A2 (en) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Solid composites of a calicum receptor-active compound
WO2008063645A1 (en) * 2006-11-20 2008-05-29 Teva Pharmaceutical Industries Ltd. Process for preparing cinacalcet
WO2008064202A2 (en) * 2006-11-20 2008-05-29 Dr. Reddy's Labortories, Ltd. Modified-release formulations of calcium receptor-active compounds
US9610327B2 (en) 2007-03-06 2017-04-04 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
CA2701638A1 (en) * 2007-04-02 2008-10-09 Concert Pharmaceuticals Inc. Pharmaceutical calcimimetics
KR101691876B1 (ko) 2007-04-25 2017-01-02 사이토크로마 인코포레이티드 비타민 d 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
CA2683628C (en) 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
ES2569483T3 (es) 2007-06-21 2016-05-11 Amgen Inc. Métodos para sintetizar cinacalcet y sales del mismo
US20090093652A1 (en) * 2007-08-16 2009-04-09 Michal Rafilovich Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
EP2300415A2 (en) * 2008-05-05 2011-03-30 Medichem, S.A. Process for controlling the particle size of a 3-(trifluoromethyl)phenyl¨-1-aminopropane derivative
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US20120009258A1 (en) * 2008-09-25 2012-01-12 Ratiopharm Gmbh Compacted cinacalcet
WO2010086129A1 (en) 2009-01-27 2010-08-05 Rathiopharm Gmbh Inclusion complex comprising cinacalcet and cyclodextrin
SI3330255T1 (sl) 2009-03-20 2021-03-31 Vertex Pharmaceuticals Incorporated Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
JP2012528084A (ja) 2009-05-27 2012-11-12 レオ ファーマ アクティーゼルスカブ 新規のカルシウム感知受容体調節化合物およびその医薬用途
WO2010136037A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2314286A1 (de) 2009-10-21 2011-04-27 Ratiopharm GmbH Schmelzgranuliertes Cinacalcet
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
JP6245983B2 (ja) 2010-08-11 2017-12-13 ドレクセル ユニバーシティ パーキンソン病におけるジスキネジアを治療するための新規d3ドーパミン受容体アゴニスト
EP2642980B8 (en) * 2010-11-23 2020-06-03 Amgen Inc. Pediatric formulation
CN103270018A (zh) 2010-11-26 2013-08-28 利奥制药有限公司 钙敏感受体激活化合物
RU2013128981A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении чувствительных к кальцию рецепторов
WO2012069421A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
WO2012069402A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Substituted cyclopentyl - azines as casr- active compounds
EP2804588B1 (en) 2012-01-17 2017-09-06 Zentiva Saglik Urunleri San. Ve Tic. A.S. Method for producing cinacalcet compositions for direct tableting
EP2819670B1 (en) 2012-02-27 2026-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical Composition and Their Administration
CN102885792A (zh) * 2012-10-12 2013-01-23 华润赛科药业有限责任公司 盐酸西那卡塞的口服固体速释制剂
PL2730279T3 (pl) 2012-11-09 2015-12-31 K H S Pharma Holding Gmbh Preparaty cynakalcetu o natychmiastowym uwalnianiu
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
ES2737756T3 (es) * 2012-12-21 2020-01-15 Synthon Bv Composición de comprimido que comprende clorhidrato de cinacalcet
KR20150136061A (ko) 2013-02-01 2015-12-04 산타 마리아 바이오테라퓨틱스, 인코포레이티드 대상에 항-액티빈-a 화합물의 투여
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
WO2014207691A1 (en) 2013-06-26 2014-12-31 Jubilant Life Sciences Limited Disintegrant free composition of cinacalcet
WO2015136329A1 (en) 2014-03-14 2015-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical composition of cinacalcet
WO2015150944A1 (en) 2014-03-29 2015-10-08 Wockhardt Limited Solid oral pharmaceutical compositions comprising cinacalcet or a salt thereof
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN104721164B (zh) * 2015-03-25 2017-07-07 河北仁合益康药业有限公司 一种盐酸西那卡塞薄膜衣片组合物
KR20180123100A (ko) 2016-03-28 2018-11-14 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법
JPWO2017170858A1 (ja) 2016-03-31 2019-02-14 インターセプト ファーマシューティカルズ, インコーポレイテッド 溶出性に優れた経口製剤
EP3668493A4 (en) * 2017-08-16 2021-08-25 Unichem Laboratories Ltd PHARMACEUTICAL COMPOSITIONS WITH CINACALCET HYDROCHLORIDE AND ONE OR MORE BINDERS
EP3773533A1 (en) 2018-03-30 2021-02-17 FTF Pharma Private Limited Liquid dosage forms of cinacalcet or salt thereof
US10920483B2 (en) 2018-10-25 2021-02-16 Mark Mutchnik Window seal for preventing water penetration
RU2750761C2 (ru) * 2019-09-17 2021-07-02 Общество с ограниченной ответственностью "АМЕДАРТ" Ядро таблетки, содержащей цинакальцета гидрохлорид
CA3172050A1 (en) * 2020-02-29 2021-09-02 Kempharm, Inc. Compositions comprising methylphenidate-prodrugs, processes of making and using the same
CN112546010A (zh) * 2020-12-02 2021-03-26 普莱赛思(天津)生命科技有限公司 一种肾病药物组合物及其制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517179A (en) 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
EP0315249A1 (en) 1987-11-02 1989-05-10 Merck & Co. Inc. Phthalazineacetic acid composition and tablet
EP0357815A1 (de) 1988-09-06 1990-03-14 Siemens Aktiengesellschaft Schaltbare Konstantstromquelle mit I2L-Gattern
IL92484A0 (en) 1988-11-30 1990-08-31 Schering Corp Sustained release diltiazem formulation
NZ231897A (en) * 1988-12-30 1992-09-25 Monsanto Co Dry water-soluble granular composition comprising glyphosate and a liquid surfactant
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US4931286A (en) 1989-04-19 1990-06-05 Aqualon Company High gloss cellulose tablet coating
DD299322A5 (de) * 1989-09-21 1992-04-09 Maschinenfabrik Rieter Ag,Ch Verfahren und vorrichtung zur feinreinigung von textilfasern
US5011068A (en) * 1989-12-05 1991-04-30 Progressive Tool & Industries Co. Automotive body framing system
US6001884A (en) 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
DE69233586T2 (de) 1991-08-23 2006-09-28 NPS Pharmaceuticals, Inc., Salt Lake City Kalzium-Rezeptor aktive Verbindungen
AU702629B2 (en) 1991-08-23 1999-02-25 Nps Pharmaceuticals, Inc. Calcium receptor-active arylalkyl amines
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
AU3777093A (en) 1993-02-23 1994-09-14 Brigham And Women's Hospital Calcium receptor-active molecules
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
UA41909C2 (uk) * 1994-07-22 2001-10-15 Елі Ліллі Енд Компані Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
EP1275635A1 (en) 1994-10-21 2003-01-15 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
GB9424766D0 (en) 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
DE19530575A1 (de) 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
JP4117506B2 (ja) 1996-05-01 2008-07-16 エヌピーエス ファーマシューティカルズ インコーポレイテッド 無機イオン活性化合物
US5837292A (en) 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
WO1998001417A1 (en) 1996-07-08 1998-01-15 Kirin Beer Kabushiki Kaisha Calcium receptor-active compounds
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
TW483881B (en) 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
WO1999009458A1 (de) 1997-08-13 1999-02-25 OCé PRINTING SYSTEMS GMBH Druck- oder kopiergerätesystem zum performanceangepassten erstellen einer vorgegebenen blattfolge von monochrom und/oder farbig bedruckten einzelblättern
EP1058538B9 (en) 1998-03-06 2013-01-02 Aptalis Pharma S.r.l. Fast disintegrating tablets
US6525084B2 (en) 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
AU760889B2 (en) 1998-10-14 2003-05-22 Ortho-Mcneil Pharmaceutical, Inc. 1,2-disubstituted cyclopropanes
UA74775C2 (en) * 1998-11-23 2006-02-15 Monsanto Ci High concentrated aqueous composition of the monoethanolammonium salt of n-phosphonomethylglycine and a method to control undesired plants
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6447809B1 (en) * 1999-05-11 2002-09-10 Metagenics, Inc. Composition for promoting healthy bone structure
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
FR2800735B1 (fr) 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
CZ20022140A3 (cs) * 1999-12-22 2002-11-13 Pharmacia Corporation Formulace inhibitoru cyklooxygenázy -2 s postupným uvolňováním
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
WO2001078725A2 (en) * 2000-04-13 2001-10-25 Synthon B.V. Modified release formulations containing a hypnotic agent
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
JP2002167327A (ja) * 2000-09-22 2002-06-11 Takeda Chem Ind Ltd 固形製剤
WO2002024230A1 (en) 2000-09-22 2002-03-28 Takeda Chemical Industries, Ltd. Solid preparations
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
IN191028B (cg-RX-API-DMAC7.html) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
EP1401503B1 (en) 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
EP1321142A1 (en) 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
WO2003086343A2 (en) 2002-04-05 2003-10-23 Cadila Healthcare Limited Fast disintegrating oral dosage forms
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
AU2003272767A1 (en) 2002-09-30 2004-04-23 Schering Corporation Use of tricyclic amides for the treatment of disorders of calcium homeostasis
GB0230015D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
AR045637A1 (es) 2003-09-12 2005-11-02 Amgen Inc Formulacion de disolucion rapida de un compuesto activo frente a los receptores de calcio
ES2358269T3 (es) 2004-08-23 2011-05-09 Teva Pharmaceutical Industries Ltd Forma cristalina del ibandronato sódico y procedimientos para su preparación.
NL1028867C2 (nl) 2005-04-26 2006-10-27 Xycarb Ceramics B V Inrichting voor het ondersteunen van een substraat alsmede een werkwijze voor het vervaardigen van een dergelijke inrichting.
EP2252901A4 (en) 2008-03-11 2012-01-25 Univ Western Ontario SYSTEM AND METHOD FOR MAGNETIC RESONANCE IMAGING

Also Published As

Publication number Publication date
SI2821067T1 (en) 2018-03-30
US9375405B2 (en) 2016-06-28
ZA200602710B (en) 2007-04-25
CY1119609T1 (el) 2018-04-04
PL2821067T3 (pl) 2018-02-28
SI3395340T1 (sl) 2019-08-30
ES2734057T3 (es) 2019-12-04
US7829595B2 (en) 2010-11-09
KR101332058B1 (ko) 2013-11-22
MXPA06002616A (es) 2006-06-05
HUE044279T2 (hu) 2019-10-28
EP2821067A1 (en) 2015-01-07
EP3395338A1 (en) 2018-10-31
CY1121820T1 (el) 2020-07-31
ES2401769T5 (es) 2020-07-01
TWI344363B (en) 2011-07-01
DK2821067T3 (en) 2017-12-04
HRP20130114T1 (xx) 2013-03-31
EA013425B1 (ru) 2010-04-30
EP1663182B2 (en) 2019-11-20
TW200518743A (en) 2005-06-16
DK3260117T3 (da) 2019-07-01
CN1946382B (zh) 2010-12-08
EP2821067B1 (en) 2017-10-25
EP3395339A1 (en) 2018-10-31
IL173737A (en) 2012-04-30
EP3395340B8 (en) 2019-12-11
TR201910447T4 (tr) 2019-08-21
CA2536487A1 (en) 2005-04-21
BRPI0414254A (pt) 2006-11-07
IS3027B (is) 2021-03-15
EP3260117B1 (en) 2019-04-17
EP3395338B1 (en) 2019-05-01
PT3395339T (pt) 2019-07-15
JP5940120B2 (ja) 2016-06-29
SG146608A1 (en) 2008-10-30
NO335739B1 (no) 2015-02-02
ES2735226T3 (es) 2019-12-17
PT1663182E (pt) 2013-03-14
DE19164145T1 (de) 2021-04-29
DK3395340T3 (da) 2019-07-15
BRPI0414254B8 (pt) 2021-05-25
SI3260117T1 (sl) 2019-08-30
SI1663182T2 (sl) 2020-02-28
EP2316442A1 (en) 2011-05-04
EP3260117A1 (en) 2017-12-27
JP5849015B2 (ja) 2016-01-27
SI1663182T1 (sl) 2013-05-31
PL1663182T3 (pl) 2013-06-28
ES2401769T3 (es) 2013-04-24
CY1121814T1 (el) 2020-07-31
CY1122259T1 (el) 2020-11-25
CA2536487C (en) 2011-10-25
PL3395338T3 (pl) 2019-10-31
BRPI0414254B1 (pt) 2021-03-02
DK3395338T3 (da) 2019-07-22
TR201910177T4 (tr) 2019-08-21
DK1663182T3 (da) 2013-04-15
SI3395339T1 (sl) 2019-08-30
JP2007505108A (ja) 2007-03-08
ES2655435T3 (es) 2018-02-20
EA200600566A1 (ru) 2006-08-25
MY142046A (en) 2010-08-30
HUE035596T2 (en) 2018-05-28
PT2821067T (pt) 2017-12-01
TR201910180T4 (tr) 2019-07-22
EP3578175B1 (en) 2022-11-30
PL3395339T3 (pl) 2019-09-30
KR20070017460A (ko) 2007-02-12
JP5026077B2 (ja) 2012-09-12
EP3395340B1 (en) 2019-04-17
AU2004279318A1 (en) 2005-04-21
PT3395338T (pt) 2019-07-23
EP1663182B1 (en) 2013-01-16
EP3578175A1 (en) 2019-12-11
AU2004279318C1 (en) 2020-06-25
PT3395340T (pt) 2019-07-15
HRP20130114T4 (hr) 2019-12-27
HUE043958T2 (hu) 2019-09-30
EP3260117B8 (en) 2019-11-27
NO20061640L (no) 2006-06-12
PL3395340T3 (pl) 2019-10-31
DK1663182T4 (da) 2020-02-17
IL173737A0 (en) 2006-07-05
ES2737348T3 (es) 2020-01-13
SI3395338T1 (sl) 2019-08-30
US20180243238A1 (en) 2018-08-30
EP1663182A1 (en) 2006-06-07
JP2012197280A (ja) 2012-10-18
DK3395339T3 (da) 2019-07-22
US20190117592A1 (en) 2019-04-25
CN1946382A (zh) 2007-04-11
EP3395339B1 (en) 2019-04-17
US20210052518A1 (en) 2021-02-25
PT3260117T (pt) 2019-07-04
HUE044822T2 (hu) 2019-11-28
TR201909267T4 (tr) 2019-07-22
EP3395340A1 (en) 2018-10-31
JP2015007089A (ja) 2015-01-15
CY1121812T1 (el) 2020-07-31
PL1663182T5 (pl) 2020-07-27
WO2005034928A1 (en) 2005-04-21
AU2004279318B2 (en) 2010-02-25
BR122018013029B1 (pt) 2022-04-12
HUE045411T2 (hu) 2019-12-30
IS8324A (is) 2006-02-23
US20200222340A1 (en) 2020-07-16
US20110136915A1 (en) 2011-06-09
AR045637A1 (es) 2005-11-02
PL3260117T3 (pl) 2019-10-31
ES2812198T1 (es) 2021-03-16
EP3395339B8 (en) 2019-12-11
US20160338975A1 (en) 2016-11-24
US20050147669A1 (en) 2005-07-07
ES2735216T3 (es) 2019-12-17

Similar Documents

Publication Publication Date Title
CA2536487C (en) Rapid dissolution formulation of a calcium receptor-active compound

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 10 SEP 2017 BY CPA GLOBAL

Effective date: 20140731

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2018 BY CPA GLOBAL

Effective date: 20170803

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2019 BY CPA GLOBAL

Effective date: 20180802

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2020 BY CPA GLOBAL

Effective date: 20190801

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2021 BY CPA GLOBAL

Effective date: 20200730

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2022 BY CPA GLOBAL

Effective date: 20210729

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2023 BY ANAQUA SERVICES

Effective date: 20220819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2024 BY ANAQUA SERVICES

Effective date: 20230823

EXPY Patent expired